SG11202004940VA - Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye - Google Patents

Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye

Info

Publication number
SG11202004940VA
SG11202004940VA SG11202004940VA SG11202004940VA SG11202004940VA SG 11202004940V A SG11202004940V A SG 11202004940VA SG 11202004940V A SG11202004940V A SG 11202004940VA SG 11202004940V A SG11202004940V A SG 11202004940VA SG 11202004940V A SG11202004940V A SG 11202004940VA
Authority
SG
Singapore
Prior art keywords
eye
treating diseases
topical composition
posterior segment
ophthalmic topical
Prior art date
Application number
SG11202004940VA
Inventor
Nortes Xavier Capdevila
Aquilué Javier Sanagustín
Gañán Maria Isabel Delgado
Original Assignee
Salvat Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salvat Lab Sa filed Critical Salvat Lab Sa
Publication of SG11202004940VA publication Critical patent/SG11202004940VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202004940VA 2017-12-04 2018-11-29 Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye SG11202004940VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382832 2017-12-04
PCT/EP2018/082999 WO2019110416A1 (en) 2017-12-04 2018-11-29 Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye

Publications (1)

Publication Number Publication Date
SG11202004940VA true SG11202004940VA (en) 2020-06-29

Family

ID=60673756

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004940VA SG11202004940VA (en) 2017-12-04 2018-11-29 Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye

Country Status (22)

Country Link
US (1) US20200390729A1 (en)
EP (1) EP3720428B1 (en)
JP (1) JP2021505554A (en)
KR (1) KR20200096569A (en)
CN (1) CN111542316A (en)
BR (1) BR112020011160A2 (en)
CA (1) CA3083835A1 (en)
CL (1) CL2020001426A1 (en)
DK (1) DK3720428T3 (en)
ES (1) ES2941036T3 (en)
FI (1) FI3720428T3 (en)
HR (1) HRP20230319T1 (en)
HU (1) HUE061852T2 (en)
MA (1) MA50991B1 (en)
MX (1) MX2020005809A (en)
PH (1) PH12020550722A1 (en)
PL (1) PL3720428T3 (en)
PT (1) PT3720428T (en)
SG (1) SG11202004940VA (en)
SI (1) SI3720428T1 (en)
WO (1) WO2019110416A1 (en)
ZA (1) ZA202003944B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117257963B (en) * 2023-11-02 2024-07-16 广州准优生物科技有限公司 Eye medicine containing umbilical mesenchymal stem cell exosome and preparation method and application thereof
CN117643573B (en) * 2024-01-29 2024-05-03 天津医科大学眼科医院 Nanometer eye drop capable of delivering medicine to posterior segment of eye, preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US9198886B2 (en) * 2006-08-16 2015-12-01 Pedro Cuevas Sánchez Use of 2,5-dihydroxybenzene for the treatment of ocular diseases
AU2012344299A1 (en) * 2011-11-30 2014-05-29 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of dry eye syndrome
ES2632012T3 (en) 2012-02-02 2017-09-07 Invesfovea S.L. Use of 2,5-dihydroxybenzene sulfonate acid for the treatment of age-related macular degeneration
ES2703324T3 (en) * 2012-03-05 2019-03-08 Univ Wayne State Identification of channelrodopsin-2 (Chop2) mutations and methods of use
AU2013254690B2 (en) * 2012-04-24 2017-12-07 Thrombogenics N.V. Anti-PDGF-C antibodies
EP2875811A1 (en) 2013-11-26 2015-05-27 Luis Antonio Outeirino Miguez Use of dobesilate for treating ocular haemorrhages

Also Published As

Publication number Publication date
CA3083835A1 (en) 2019-06-13
ES2941036T3 (en) 2023-05-16
CN111542316A (en) 2020-08-14
KR20200096569A (en) 2020-08-12
PH12020550722A1 (en) 2021-02-15
AU2018378981A1 (en) 2020-07-16
CL2020001426A1 (en) 2020-11-06
BR112020011160A2 (en) 2020-11-17
MA50991B1 (en) 2023-03-31
ZA202003944B (en) 2022-12-21
HUE061852T2 (en) 2023-08-28
JP2021505554A (en) 2021-02-18
PL3720428T3 (en) 2023-05-08
PT3720428T (en) 2023-04-03
US20200390729A1 (en) 2020-12-17
WO2019110416A1 (en) 2019-06-13
DK3720428T3 (en) 2023-03-20
FI3720428T3 (en) 2023-03-30
HRP20230319T1 (en) 2023-05-12
MX2020005809A (en) 2020-08-20
EP3720428B1 (en) 2023-01-11
MA50991A (en) 2020-10-14
SI3720428T1 (en) 2023-05-31
EP3720428A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
PL3399962T3 (en) Ophthalmic composition for treatment of dry eye disease
IL277333A (en) Methods for treating ocular diseases
EP3390634A4 (en) Compositions and methods for treatment of eye diseases
IL281773A (en) Ophthalmic composition for treatment of dry eye disease
EP3515444A4 (en) Composition for treating ocular diseases and methods of usage and making
IL273531A (en) Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
EP3481411A4 (en) Treatment for glaucoma and other eye diseases
GB2541840B (en) Ophthalmic composition for the treatment of ocular infection
EP3713553A4 (en) Compositions and methods for treatment of eye diseases
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
EP3618868A4 (en) Methods and compositions for treating allergic ocular diseases
ZA202003944B (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
IL269698B (en) Methods of preventing or treating ophthalmic diseases
EP3265103A4 (en) Compositions and methods for treating ocular diseases
EP3643297A4 (en) Ophthalmic composition for glaucoma treatment
PL3515409T3 (en) Complex and compositions for the treatment of ophthalmic and dermatological diseases
IL282898A (en) Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases
PL3407879T3 (en) Ophthalmic gabapentin for the treatment of corneal ulcers
EP3402511A4 (en) Compositions and methods for treatment of ocular diseases
IL280588A (en) Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases
EP3310396A4 (en) Therapeutic nanofiber hydrogels for local treatment of brain-related diseases
PL3302463T3 (en) Use of 3-deoxyanthocyanidins for treating ocular diseases
IT201700099156A1 (en) Nanoparticle ophthalmic composition for the treatment of eye disorders or diseases
IL280952A (en) Methods and compositions for drugs to treat ophthalmic diseases
EP3170500A4 (en) Prophylactic or therapeutic agent for diseases of posterior segment of eye